Evidence map›Paper›PMID 24594871›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder.

Sonam Dodhia, Avinash Hosanagar, Daniel A Fitzgerald, Izelle Labuschagne, Amanda G Wood, Pradeep J Nathan, K Luan Phan

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pharmacotherapy for social anxiety disorder (SAnD).The Cochrane database of systematic reviews · 2017
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Oxytocin induces long-lasting adaptations within amygdala circuitry in autism: a treatment-mechanism study with randomized placebo-controlled design.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  11. Trial
  12. Oxytocin increases eye gaze in schizophrenia.Schizophrenia research · 2019
    Trial
  13. Trial
  14. Trial
  15. Intranasal Oxytocin Normalizes Amygdala Functional Connectivity in Posttraumatic Stress Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Trial
  16. Intranasal Oxytocin Administration Dampens Amygdala Reactivity towards Emotional Faces in Male and Female PTSD Patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Trial
  17. Intranasal Oxytocin Affects Amygdala Functional Connectivity after Trauma Script-Driven Imagery in Distressed Recently Trauma-Exposed Individuals.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Trial
  18. Trial
  19. Trial
  20. Oxytocin modulation of amygdala functional connectivity to fearful faces in generalized social anxiety disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015
    Trial

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sonam DodhiaDepartment of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.
Avinash Hosanagar1] Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA [2] Mental Health Service, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Daniel A Fitzgerald1] Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA [2] Mental Health Service Line, Jesse Brown VA Medical Center, Chicago, IL, USA.
Izelle LabuschagneSchool of Psychological Sciences, Monash University, Melbourne, Victoria, Australia.
Amanda G Wood1] School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia [2] School of Psychology, University of Birmingham, Birmingham, UK.
Pradeep J Nathan1] School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia [2] Department of Psychiatry, Cambridge University, Cambridge, UK.
K Luan Phan1] Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA [2] Mental Health Service Line, Jesse Brown VA Medical Center, Chicago, IL, USA [3] Departments of Psychology and Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Generalized social anxiety disorder (GSAD) is characterized by aberrant patterns of amygdala-frontal connectivity to social signals of threat and at rest. The neuropeptide oxytocin (OXT) modulates anxiety, stress, and social behaviors. Recent functional neuroimaging studies suggest that these effects are mediated through OXT's effects on amygdala reactivity and/or amygdala-frontal connectivity. The aim of the current study was to examine OXT's effects on amygdala-frontal resting-state functional connectivity (rsFC) in GSAD patients and healthy controls (HCs). In a randomized, double-blind, cross-over design, 18 GSAD and 18 HC participants received intranasal OXT (24 IU or 40.32 μg) or placebo (PBO) before resting-state functional magnetic resonance imaging. In individuals with GSAD, OXT enhanced rsFC of the left and right amygdala with rostral anterior cingulate cortex (ACC)/medial prefrontal cortex (mPFC), and in doing so, reversed (ie, 'normalized') the reduced amygdala-frontal connectivity observed relative to HCs evident on PBO. Higher social anxiety severity in GSAD subjects correlated with lower amygdala-ACC/mPFC connectivity on PBO and higher social anxiety also correlated with greater enhancement in amygdala-frontal connectivity induced by OXT. These findings show that OXT modulates a neural circuit known for social threat processing and emotion regulation, suggesting a neural mechanism by which OXT may have a role in the pathophysiology and treatment of social anxiety disorder.

Indexed as

Administration, IntranasalAdultAmygdalaAnxiety DisordersCentral Nervous System AgentsCross-Over StudiesDouble-Blind MethodFrontal LobeFunctional LateralityHumansMagnetic Resonance ImagingMaleMiddle AgedNeural PathwaysOxytocinPsychiatric Status Rating ScalesCentral Nervous System AgentsOxytocin

Identifiers

PMID24594871
PMCPMC4104324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.